C12N 2710/16111
Cytomegalovirus
Official title: Cytomegalovirus, e.g. human herpesvirus 5
C12N2710/16111 (Cytomegalovirus) appears on 538 US grants and 802 published applications in this corpus.
Search patents in C12N- Granted patents
- 538
- Published applications
- 802
- Assignees
- 398
- Inventors
- 1,399
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 12 | 0 |
| 1997 | 7 | 0 |
| 1998 | 27 | 0 |
| 1999 | 15 | 0 |
| 2000 | 16 | 0 |
| 2001 | 17 | 2 |
| 2002 | 6 | 9 |
| 2003 | 14 | 17 |
| 2004 | 9 | 20 |
| 2005 | 3 | 12 |
| 2006 | 5 | 14 |
| 2007 | 7 | 6 |
| 2008 | 9 | 18 |
| 2009 | 9 | 11 |
| 2010 | 5 | 18 |
| 2011 | 5 | 15 |
| 2012 | 6 | 13 |
| 2013 | 9 | 25 |
| 2014 | 10 | 36 |
| 2015 | 15 | 32 |
| 2016 | 27 | 37 |
| 2017 | 18 | 36 |
| 2018 | 23 | 39 |
| 2019 | 30 | 45 |
| 2020 | 30 | 58 |
| 2021 | 34 | 68 |
| 2022 | 29 | 81 |
| 2023 | 42 | 67 |
| 2024 | 34 | 47 |
| 2025 | 33 | 47 |
| 2026 | 16 | 29 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2710/16122New viral proteins or individual genes, new structural or functional aspects ofIndexing code277
- C12N 2710/16134Use of virus or viral component as vaccineIndexing code258
- C12N 2710/16141Use of virus, viral particle or viral elements as a vectorIndexing code105
- C12N 2710/16161Methods of inactivation or attenuationIndexing code42
- C12N 2710/16171Demonstrated in vivo effectIndexing code41
- C12N 2710/16151Methods of production or purification of viral materialIndexing code34
- C12N 2710/16121Viruses as suchIndexing code26
- C12N 2710/16133Use of viral protein as therapeutic agent other than vaccineIndexing code9
Recent patents
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Mammalian expression vectors30 Jun 2026US 12,668,809 B2Biocon Biologics Limited
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- High affinity engineered T-cell receptors targeting cmv infected cells9 Jun 2026US 12,649,772 B2Board of Regents, The University of Texas System
- Methods and vaccines for inducing immune responses to multiple different MHC molecules12 May 2026US 12,622,956 B2Mayo Foundation for Medical Education and Research
- Modified cytomegalovirus proteins and stabilized complexes27 Aug 2026US 2026/0250330 A1Glaxosmithkline Biologicals SA
- Human cytomegalovirus gb polypeptide20 Aug 2026US 2026/0240988 A1Pfizer Inc.
- T cell-directed anti-aging and anti-cancer vaccines against commensal cytomegalovirus6 Aug 2026US 2026/0224692 A1The General Hospital Corporation
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Stem cell reprogramming with gene-enhanced stem cells23 Jul 2026US 2026/0207672 A1
Most cited
By later US patents
- Deoxyribonucleic acid segment from a virus193US 4,968,615 ACiba-Geigy Corporation · 1990
- Production of adeno-associated virus in insect cells138US 6,723,551 B2The United States of America as represented by the Department of Health and Human Services · 2004
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Human cytomegalovirus RNA vaccines130US 10,064,935 B2ModernaTX, Inc. · 2018
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998